enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update

- Ended the quarter with $39.1 million cash and investments on hand sufficient to fund operations, through the end of 2025, including potential PMA approval of VenoValve- Positive interim venous ulcer healing data showing significant improvement …
Jetzt den vollständigen Artikel lesen